3rd Dose of Covaxin Holds Promise, No Serious Side Effects: ICMR As India Begins Booster Drive

The medical research body in its tweet further highlighted the benefits of getting Covaxin's precautionary dose.

Updated: January 10, 2022 10:49 AM IST

By India.com News Desk | Edited by Kritika Bansal

Covaxin, covid vaccine, india, ICMR study, India, covid vaccines, covaxin vaccine
The protective efficacy of Bharat Biotech's Covaxin following two and three-dose immuniszations against the Delta variant and the efficacy of the Covaxin against Omicron variants were studied in a Syrian hamster model, the study said. (File Photo)

New Delhi: As the government begins the next phase of its COVID-19 vaccination drive by administering precaution doses to frontline, healthcare workers and senior citizens with co-morbidities from today, the Indian Council of Medical Research (ICMR) has said the third dose of Bharat Biotech’s Covaxin holds promise.

Also Read:

“Third dose of COVAXIN holds promise,” the ICMR tweeted on Sunday (January), just a day before the booster dose drive

The medical research body in its tweet further highlighted the benefits of getting Covaxin’s precautionary dose. It said, “Reassuring information on safety and immunogenicity of a booster dose of Covaxin administered six months after completion of a two dose primary vaccination series with Covaxin.”

“Good neutralising antibody titre detected against homologous and heterologous SARS-CoV 2 variants following booster. Reactogenicity in both vaccine and placebo arm of the trial was minimal and comparable. No serious adverse events were reported,” the tweet said.

On December 25, 2021, Prime Minister Narendra Modi announced that from January 3, 2022 vaccination will start for the children in the age group of 15-18 years and further announced administration of precaution dose for healthcare and frontline workers from January 10, 2022.

“This has been done in the light of the amount of time that the frontline workers and health care workers spend in the service of COVID-19 infected patients. In India, this has been called ‘precaution dose’, not booster dose. The decision on precaution dose will strengthen the confidence of healthcare and frontline workers,” the Prime Minister’s office said.

The Prime Minister also announced that option of precaution dose will be available to senior citizens above 60 years of age with co-morbidities on the advice of their doctors from January 10, 2022.

With the administration of more than 89 lakh doses (89,28,316) vaccine doses in the last 24 hours, India’s COVID-19 vaccination coverage has exceeded 151.57 crore (1,51,57,60,645) as per provisional reports till 7 am today, the health ministry said.

(With inputs from PTI)

For breaking news and live news updates, like us on Facebook or follow us on Twitter and Instagram. Read more on Latest India News on India.com.

Topics

Published Date: January 10, 2022 10:47 AM IST

Updated Date: January 10, 2022 10:49 AM IST